JP4138485B2 - 治療薬剤、特に骨粗しょう症を治療するための有効活性化合物を開発するための試験システム - Google Patents

治療薬剤、特に骨粗しょう症を治療するための有効活性化合物を開発するための試験システム Download PDF

Info

Publication number
JP4138485B2
JP4138485B2 JP2002559678A JP2002559678A JP4138485B2 JP 4138485 B2 JP4138485 B2 JP 4138485B2 JP 2002559678 A JP2002559678 A JP 2002559678A JP 2002559678 A JP2002559678 A JP 2002559678A JP 4138485 B2 JP4138485 B2 JP 4138485B2
Authority
JP
Japan
Prior art keywords
clc
channel
chloride
cells
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002559678A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004531227A5 (https=
JP2004531227A (ja
Inventor
イェンチュ、トーマス・ヨット
Original Assignee
ノイロサーチ アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノイロサーチ アクティーゼルスカブ filed Critical ノイロサーチ アクティーゼルスカブ
Publication of JP2004531227A publication Critical patent/JP2004531227A/ja
Publication of JP2004531227A5 publication Critical patent/JP2004531227A5/ja
Application granted granted Critical
Publication of JP4138485B2 publication Critical patent/JP4138485B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2002559678A 2001-01-23 2002-01-17 治療薬剤、特に骨粗しょう症を治療するための有効活性化合物を開発するための試験システム Expired - Fee Related JP4138485B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10102977A DE10102977A1 (de) 2001-01-23 2001-01-23 Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose
PCT/DK2002/000038 WO2002059612A2 (en) 2001-01-23 2002-01-17 Animal model and cell-line expressing modified chlorine channel

Publications (3)

Publication Number Publication Date
JP2004531227A JP2004531227A (ja) 2004-10-14
JP2004531227A5 JP2004531227A5 (https=) 2007-10-18
JP4138485B2 true JP4138485B2 (ja) 2008-08-27

Family

ID=7671497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002559678A Expired - Fee Related JP4138485B2 (ja) 2001-01-23 2002-01-17 治療薬剤、特に骨粗しょう症を治療するための有効活性化合物を開発するための試験システム

Country Status (6)

Country Link
US (1) US7534425B2 (https=)
EP (1) EP1360204B1 (https=)
JP (1) JP4138485B2 (https=)
AU (1) AU2002224759A1 (https=)
DE (1) DE10102977A1 (https=)
WO (1) WO2002059612A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1360504B1 (en) * 2001-01-23 2006-09-13 Pharmos Bioscience A/S Method for screening compounds for activity in treating an osteoclast related bone disease
US20030215787A1 (en) * 2002-01-23 2003-11-20 Wen-Pin Yang Modulators of the CLC-7 chloride channel and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states
AU2003214920A1 (en) 2002-02-04 2003-09-02 Millennium Pharmaceuticals Inc. Methods and compositions for treating hematological disorders
GB0227243D0 (en) * 2002-11-21 2002-12-31 Univ Aberdeen Genetic markers for bone mass
US7785807B2 (en) * 2004-12-13 2010-08-31 Monell Chemical Senses Center Voltage-gated, pH-sensitive anion channel and its novel splice variant involved in taste sensation
WO2008101022A2 (en) * 2007-02-13 2008-08-21 The Nielsen Company (Us), Llc Methods and apparatus to reach through to business logic services
US8741591B2 (en) 2009-10-09 2014-06-03 The Research Foundation For The State University Of New York pH-insensitive glucose indicator protein
EP2420830B1 (en) * 2010-08-16 2016-11-16 Forschungsverbund Berlin e.V. Chloride transporter ClC-7 and cell-based screening method
WO2017049178A1 (en) * 2015-09-16 2017-03-23 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method of making trabecular bone
US10640766B2 (en) * 2017-04-12 2020-05-05 Tempo Bioscience, Inc. Biosensors for chloride ions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434058A (en) * 1993-02-09 1995-07-18 Arch Development Corporation Apolipoprotein B MRNA editing protein compositions and methods
CA2305714A1 (en) * 1997-10-01 1999-04-08 Yale University Methods to modulate blood pressure and diagnose bartter's syndrome type iii
OA11665A (en) 1998-10-22 2004-12-08 Neurosearch As Substituted phenyl derivatives, their preparation and use.
US6686193B2 (en) * 2000-07-10 2004-02-03 Vertex Pharmaceuticals, Inc. High throughput method and system for screening candidate compounds for activity against target ion channels

Also Published As

Publication number Publication date
EP1360204A2 (en) 2003-11-12
WO2002059612A2 (en) 2002-08-01
WO2002059612A3 (en) 2002-12-12
DE10102977A1 (de) 2002-08-01
JP2004531227A (ja) 2004-10-14
US20040265837A1 (en) 2004-12-30
US7534425B2 (en) 2009-05-19
EP1360204B1 (en) 2014-04-30
AU2002224759A1 (en) 2002-08-06

Similar Documents

Publication Publication Date Title
Young, 3rd et al. Transgenesis and the study of expression, cellular targeting and function of oxytocin, vasopressin and their receptors
US8871996B2 (en) Mice expressing human voltage-gated sodium channels
US8486647B2 (en) Neuropeptide release assay for sodium channels
Hermiston et al. Chimeric-transgenic mice represent a powerful tool for studying how the proliferation and differentiation programs of intestinal epithelial cell lineages are regulated.
JP4138485B2 (ja) 治療薬剤、特に骨粗しょう症を治療するための有効活性化合物を開発するための試験システム
JP2004536585A (ja) トル／インターロイキン−１受容体アダプタータンパク質（ｔｉｒａｐ）
US5750826A (en) Bradykinin B2 receptor modified transgenic non-human animals
US20090100532A1 (en) Transgenic mice expressing hypersensitive nicotinic receptors
Zhang et al. Generation of a conditional allele of the CBP gene in mouse
US6753456B2 (en) Point mutant mice with hypersensitive alpha 4 nicotinic receptors: dopaminergic pathology and increased anxiety
US6284944B1 (en) Gene-targeted non-human mammal with a human fad presenilin mutation and generational offspring
Oh-Hora et al. Function of Orai/Stim proteins studied in transgenic animal models
EP1116790A1 (en) Murine models characterized by conditional mutation of SMN gene - use for study of spinal muscular atrophy and other neurodegenerative diseases and muscular myopathies
WO2003003013A1 (en) Non-nuclear effects of thyroid hormone
US20050044581A1 (en) Animals and cells containing a mutated alpha2/omega1 gene
US20030041341A1 (en) Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in DNA encoding 4E-BP1
US20090233840A1 (en) Modified Dynorphin Expression in Animals and Identification of Compounds for Treatment of Obesity and Diabetes
JPWO2004108920A1 (ja) 抗肥満薬のスクリーニング方法及び肥満モデル動物
Feldstein Construction of a targeting vector for the analysis of the neuroendocrine function of chromogranin A
Hawkins Investigation of annexin function by targeted gene disruption
Chenaux The Intracellular Domain of EPHB1 Is Required for Axon Pathfinding at the Optic Chiasm and Corpus Callosum
WO2007020244A1 (en) The mitochondrial rhomboid protease parl as a target for lymphoma
Judd-Mole Establishing Drosophila as a research model for the study of Voltage Gated Chloride Channelopathies
Hinds CaMKII at a central synapse: α-calcium/calmodium protien kinase II and synaptic plasticity at CA3 Schaffer collateral--CA1 synapses in the mammalian hippocampus
JPH11285332A (ja) ベータセルリン遺伝子の発現不全動物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040908

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20060817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070802

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20070802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080107

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080328

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080530

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080605

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110613

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120613

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120613

Year of fee payment: 4

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120613

Year of fee payment: 4

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120613

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130613

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130613

Year of fee payment: 5

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees